Synthesis of P1, P3-Distavudine-5′, 5′-Triphosphate

Shan Shan Gong; Qi Sun

doi:10.4028/www.scientific.net/AMR.1023.75

Paper Titles

Preparation of Modified 1,6-Hexanediamines
p.59

Synthesis of Guanosine-Containing Dinucleoside Triphosphates
p.63

Sustained Release Properties of Aminophylline Sustained Release Tablets Based on Exfoliated Graphite
p.67

Research on Allelochemicals with Material Properties Exuded by Submerged Freshwater Macrophyte Elodea nuttallii
p.71

Synthesis of P¹, P³-Distavudine-5′, 5′-Triphosphate
p.75

Practical Synthesis of 5-Hydroxymethyl-2′-Deoxycytidine
p.79

Synthesis of Symmetrical P¹,P²-Dinucleoside Diphosphates with Pyrimidine Bases
p.83

Efficient Synthesis of Pyrimidine-Nucleoside Monophosphates from H-Phosphonates
p.87

Synthesis of Dinucleoside Triphosphates with Pyrimidine Bases
p.91

HomeAdvanced Materials ResearchAdvanced Materials Research Vol. 1023Synthesis of P1, P3-Distavudine-5′,...

Synthesis of P¹, P³-Distavudine-5′, 5′-Triphosphate

Abstract:

A practical method for the preparation of P¹,P³-distavudine triphosphate has been developed. Stavudine diphosphate was first synthesized from stavudine phosphoropiperidate. The coupling of stavudine diphosphate with excess stavudine phosphoropiperidate in the presence of 4,5-dicyanoimidazole afforded symmetrical distavudine triphosphate in good yield.

You might also be interested in these eBooks

View Preview

Info:

Periodical:

Advanced Materials Research (Volume 1023)

Pages:

75-78

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.1023.75

Citation:

Cite this paper

Online since:

August 2014

Authors:

Shan Shan Gong, Qi Sun*

Keywords:

Activation, Antiviral Nucleoside, Dinucleoside Triphosphate, Stavudine

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

Citation:

* - Corresponding Author

References

[1] R.K. Robins, Med. Res. Rev. Vol. 3 (1985) p.273.

Google Scholar

[2] R.J. Jones, N. Bischofberger, Antiviral Res. Vol. 27 (1995) p.1.

Google Scholar

[3] D. Clercq, Molecular Targets for Antiviral Agents. Vol. 297 (2000) p.1.

Google Scholar

[4] E. De Clercq, J. Neyts, Handb. Exp. Pharmacol. Vol. 189 (2009) p.53.

Google Scholar

[5] B. Öberg, Antiviral Res. Vol. 71 (2006) p.90.

Google Scholar

[6] M. Baba, R. Pauwels, P. Herdewijn, E. De Clercq, J. Desmyter, M. Vandeputte, Biochem. Biophys. Res. Commun. Vol. 142 (1987), p.128.

Google Scholar

[7] J. Balzarini, S. Aquaro, T. Knispel, C. Rampazzo, V. Bianchi, C. -F. Perno, E. De Clercq, C. Meier, Mol. Pharmacol. Vol. 58 (2000) p.928.

DOI: 10.1124/mol.58.5.928

Google Scholar

[8] E. De Clercq, J. Med. Chem. Vol. 38 (1995) p.2491.

Google Scholar

[9] D. Saboulard, L. Naesens, D. Cahard, A. Salgado, R. Pathirana, S. Velazquez, C. McGuigan, E. De Clercq, J. Balzarini, Mol. Pharmacol. Vol. 56 (1999) p.693.

Google Scholar

[10] S. Yang, C. Pannecouque, P. Herdewijn, Chemistry Biodiversity. Vol. 9 (2012), p.2186.

Google Scholar

[11] S.R. Shaver, J.L. Rideout,W. Pendergast, J.G. Douglass, E.G. Brown, J.L. Boyer, R.I. Patel, C.C. Redick, A.C. Jones, M. Picher, B.R. Yerxa, Purinergic Signalling Vol. 1 (2005), p.183.

DOI: 10.1007/s11302-005-0648-2

Google Scholar

[12] W. Pendergast, B.R. Yerxa, J.G. Douglass, S.R. Shaver, R.W. Dougherty, C.C. Redick, I.F. Sims, J.L. Rideout, Bioorg. Med. Chem. Lett. Vol. 11 (2001), p.157.

DOI: 10.1016/s0960-894x(00)00612-0

Google Scholar

[13] S. Mohamady, S.D. Taylor, J. Org. Chem. Vol. 76 (2011), p.6344.

Google Scholar

[14] S. Mohamady, A. Desoky, S.D. Taylor, Org. Lett. Vol. 14 (2012), p.402.

Google Scholar

[15] Q. Sun, S. Gong, J. Sun, C. Wang, S. Liu, G. Liu, C. Ma, Tetrahedron Lett. Vol. 55 (2014), p.2114.

Google Scholar